These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 3040368)

  • 1. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
    Grace ME; Fu KP; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of beta-lactamase inhibitors.
    Jackson D
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):37S-39S. PubMed ID: 2041830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin].
    Cullmann W; Binder S; Stieglitz M
    Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 6. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX; McElrath MJ; Neu HC
    Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activity of a sulphone beta-lactamase inhibitor, YTR 830.
    Moosdeen F; Williams J; Yamabe S
    Chemioterapia; 1987 Jun; 6(2 Suppl):206-7. PubMed ID: 2855613
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
    Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
    Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of five irreversible inhibitors on beta-lactamase from Shigella flexneri UCSF-129.
    Campos M; Alarcón MA; González H; Sánchez R
    Microbios; 1993; 76(308):171-9. PubMed ID: 8302198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of beta-lactamase inhibitors.
    Sutherland R
    J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming enzymatic resistance in bacteria: impact on future therapy.
    Labia R; Barthélémy M; Péduzzi J; Morand A; Tiwari K; Kazmierczak A
    J Int Med Res; 1990; 18 Suppl 4():48D-57D. PubMed ID: 2282969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC; Barry AL
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
    Prabhakaran K; Harris EB; Randhawa B; Hastings RC
    Microbios; 1995; 81(328):177-85. PubMed ID: 7752957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetics of SHV-2 plasmid-mediated beta-lactamase compared to those of the parent enzyme from which it is derived.
    Labia R; Morand A; Tiwari K; Pitton JS; Sirot D; Sirot J; Ben Yaghlane H; Boujenah A
    Drugs Exp Clin Res; 1988; 14(5):335-9. PubMed ID: 3065020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Activity of sulbactam and clavulanic acid, alone and combined, on Acinetobacter calcoaceticus].
    Kitzis MD; Goldstein FW; Labia R; Acar JF
    Ann Microbiol (Paris); 1983; 134A(2):163-8. PubMed ID: 6307103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriological investigations with beta-lactamase inhibitors.
    Ullmann U
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jun; 252(2):222-9. PubMed ID: 6289565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of three beta-lactamase inhibitors: YTR830H, sulbactam and clavulanic acid on the growth of human cells in culture.
    Yamabe S; Adachi K; Watanabe M; Ueda S
    Chemioterapia; 1987 Oct; 6(5):337-40. PubMed ID: 2827899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the activity of first and second generation cephalosporins and their combinations with beta-lactamase inhibitors against Bacteroides fragilis.
    Martin MA; Liebana J; Castillo AM; Gutierrez J; Piédrola G
    Microbios; 1991; 67(272-273):195-202. PubMed ID: 1779879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro comparison of the beta lactamase-inhibitory action of clavulanic acid and sulbactam in ampicillin-resistant enterobacteria].
    Grimm H
    Arzneimittelforschung; 1987 Oct; 37(10):1116-9. PubMed ID: 3501722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.
    Hedberg M; Lindqvist L; Tunér K; Nord CE
    J Antimicrob Chemother; 1992 Jul; 30(1):17-25. PubMed ID: 1331018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.